Xilio Therapeutics (XLO) Receivables (2024)
Xilio Therapeutics (XLO) reported Receivables of $30.0 million for Q1 2024.
Xilio Therapeutics (XLO) Receivables (2024) Analysis & Trends
Xilio Therapeutics (XLO) has 1 years of Receivables data on file, last reported at $30.0 million in Q1 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,741.39 Bn | 66,741.11 Bn | - | - |
| 2 | Nanobiotix | 1,913.26 Bn | 1,913.20 Bn | - | 4.97 Mn |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.02 Bn | 466.23 Bn | 1.35 Bn | 938.02 Mn |
| 5 | Vertex Pharmaceuticals | 122.17 Bn | 114.92 Bn | 2.59 Bn | 2.00 Bn |
| 6 | Regeneron Pharmaceuticals | 69.85 Bn | 61.10 Bn | 3.31 Bn | 5.73 Bn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.60 Bn | 50.42 Bn | 1.41 Bn | 1.93 Bn |
| 9 | Alnylam Pharmaceuticals | 37.39 Bn | 34.38 Bn | 959.66 Mn | 883.96 Mn |
| 10 | Xilio Therapeutics | 148.60 Mn | -1.70 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2024 | 30.00 Mn |